Vanda Pharmaceuticals Inc. (VNDA) stock
VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3055% below fair value
$3.75−0.06 (-1.57%)
Close on Nov 18, 2026Market cap $226.76MP/E –Yield –
Vanda Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Vanda Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was -$139.14M. For fiscal 2025 it was -$109.44M. The highest annual figure on record is $169.34M in fiscal 2009.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$109.44M | – |
| FY2024 | Dec 31, 2024 | -$15.76M | -223.1% |
| FY2023 | Dec 31, 2023 | $12.80M | -60.0% |
| FY2022 | Dec 31, 2022 | $31.98M | -50.2% |
| FY2021 | Dec 31, 2021 | $64.21M | +24.0% |
| FY2020 | Dec 31, 2020 | $51.78M | +12.7% |
| FY2019 | Dec 31, 2019 | $45.95M | +53.2% |
| FY2018 | Dec 31, 2018 | $29.99M | – |
| FY2017 | Dec 31, 2017 | -$1.98M | – |
| FY2016 | Dec 31, 2016 | -$8.10M | -165.1% |
| FY2015 | Dec 31, 2015 | $12.45M | – |
| FY2014 | Dec 31, 2014 | -$81.55M | – |
| FY2013 | Dec 31, 2013 | -$39.59M | – |
| FY2012 | Dec 31, 2012 | -$44.92M | – |
| FY2011 | Dec 31, 2011 | -$28.41M | – |
| FY2010 | Dec 31, 2010 | -$10.90M | -106.4% |
| FY2009 | Dec 31, 2009 | $169.34M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$28.44M | – |
| Q2 FY2026 | Jun 30, 2026 | -$31.07M | – |
| Q1 FY2026 | Mar 31, 2026 | -$50.22M | – |
| Q4 FY2025 | Dec 31, 2025 | -$29.42M | – |
| Q3 FY2025 | Sep 30, 2025 | -$31.63M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.25M | – |
| Q1 FY2025 | Mar 31, 2025 | -$33.15M | -537.9% |
| Q4 FY2024 | Dec 31, 2024 | -$1.82M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.58M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.93M | – |
| Q1 FY2024 | Mar 31, 2024 | $7.57M | -76.2% |
| Q4 FY2023 | Dec 31, 2023 | -$3.73M | -139.6% |
| Q3 FY2023 | Sep 30, 2023 | -$2.05M | -116.0% |
| Q2 FY2023 | Jun 30, 2023 | -$13.22M | -332.5% |
| Q1 FY2023 | Mar 31, 2023 | $31.80M | +686.0% |
| Q4 FY2022 | Dec 31, 2022 | $9.42M | -64.6% |
| Q3 FY2022 | Sep 30, 2022 | $12.84M | +36.6% |
| Q2 FY2022 | Jun 30, 2022 | $5.69M | -70.1% |
| Q1 FY2022 | Mar 31, 2022 | $4.05M | -56.0% |
| Q4 FY2021 | Dec 31, 2021 | $26.61M | +37.8% |
| Q3 FY2021 | Sep 30, 2021 | $9.40M | +0.2% |
| Q2 FY2021 | Jun 30, 2021 | $19.02M | -20.8% |
| Q1 FY2021 | Mar 31, 2021 | $9.19M | – |
| Q4 FY2020 | Dec 31, 2020 | $19.30M | +97.1% |
| Q3 FY2020 | Sep 30, 2020 | $9.37M | +56.3% |
| Q2 FY2020 | Jun 30, 2020 | $24.01M | +17.0% |
| Q1 FY2020 | Mar 31, 2020 | -$907.00K | -109.4% |
| Q4 FY2019 | Dec 31, 2019 | $9.79M | -35.9% |
| Q3 FY2019 | Sep 30, 2019 | $6.00M | -31.0% |
| Q2 FY2019 | Jun 30, 2019 | $20.52M | +367.2% |
| Q1 FY2019 | Mar 31, 2019 | $9.64M | +488.7% |
| Q4 FY2018 | Dec 31, 2018 | $15.26M | +340.4% |
| Q3 FY2018 | Sep 30, 2018 | $8.69M | +301.0% |
| Q2 FY2018 | Jun 30, 2018 | $4.39M | – |
| Q1 FY2018 | Mar 31, 2018 | $1.64M | – |
| Q4 FY2017 | Dec 31, 2017 | $3.47M | – |
| Q3 FY2017 | Sep 30, 2017 | $2.17M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.26M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.36M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.18M | – |
See a number that looks wrong?